New Glykon Hydroxycitrate (HCA) Patent, Litigation against Renaissance Herbs Inc. and Alex Moffett
December 15, 2006
Las Vegas, NV, December 15, 2006 — Glykon Technologies Group LLC has received Notice of Allowance for a new US Patent entitled, “Method for Stable and Controlled Delivery of (–)-Hydroxycitric Acid.” This patent teaches methods for the pharmaceutical delivery of potassium, sodium and other hygroscopic salts of hydroxycitric acid (HCA from Garcinia cambogia and related species). Pure forms of these HCA salts normally cannot be delivered in capsules or tablets and until now have not be available for use in oral supplements.
Purity and proper manufacture are important. Work from Europe based on Super CitriMax has indicated a lack of benefit, for example, to insulin levels and also has found poor performance compared with more pure potassium HCA salts. (1, 2) This confirms Glykon’s US Patent 6,476,071 report that rats on a high fat diet received no weight control benefits from potassium-calcium HCA, whereas potassium hydroxycitrate strongly reduced weight gain and reduced insulin levels. Only Glykon holds the rights to make claims regarding the impact of HCA on the regulation of insulin and blood sugar, modulation of leptin and glucocorticoids, improvements in bone mineralization, the regulation of immune function, normalization of blood pressure and control of inflammation.
Pursuant to a complaint filed March 15, 2005 as Glykon Technologies Group, LLC v. Renaissance Herbs, Inc., et al. in Los Angeles Superior Court, Case No. BC 330334, Glykon is suing Renaissance Herbs, Inc. of Chatsworth, California and its president, Alex S. Moffett (also known as S. Alexander Moffett and Scott A. Moffett). Renaissance Herbs’ subsidiaries also potentially affected by the lawsuit are Ayurceutics (Chatsworth, California) and Dhanvantari Botanicals Pvt. Ltd. (India). The filing of litigation followed Glykon's termination on February 4, 2005 of a licensing agreement granting use of certain Glykon intellectual property to Renaissance Herbs, Inc. (“RHI”). Inter alia, the Complaint alleges fraud, breach of contract, and failure to provide accounting either according to the ordinary terms of the contract or when specifically requested and required in response to termination. RHI, further, has attempted to misappropriate certain IP belonging to Glykon and made filings to the USPTO not listing the rightful inventors. See PRNewswire at http://www.prnewstoday.com/release.htm?cat=medical-pharmaceuticals&dat=20060822&rl=SFTU09522082006-1.
(1) Leonhardt M, et al. Effect of hydroxycitrate on respiratory quotient, energy expenditure, and glucose tolerance in male rats after a period of restrictive feeding. Nutrition. 2004 Oct;20(10):911-5.
(2) Louter-van de Haar J, et al. Comparison of the effects of three different (–)-hydroxycitric acid preparations on food intake in rats. Nutr Metab (Lond). 2005 Sep 13;2(1):23.